The OC Premium Small Companies Fund's holding in Sirtex Medical (SRX) was the standout in January, finishing the month 20.2% higher

The OC Premium Small Companies Fund's holding in Sirtex Medical (SRX) was the standout in January, finishing the month 20.2% higher. SRX is a medical device group whose primary objective is to manufacture and distribute liver cancer treatments. In early January, SRX announced quarterly dose sales for its key SIR-Spheres microspheres (targeted radioactive liver cancer treatment), which grew 18.7%. This was the 38th consecutive quarter of dose sales growth for SRX. Along with its product development pipeline, we continue to see many more quarters of growth ahead for Sirtex. Our recent decision to increase the cyclical exposure within the portfolio was rewarded in January with Servcorp (SRV), CSR Limited (CSR) and Fletcher Building (FBU) all posting gains of 5-10%. The OC premium small companies fund has a five-year track record of returning 24.7% per annum. The new monthly fund update is here: (VIEW LINK)


2 topics

OC Funds Management (OC) is a boutique small cap specialist which was founded by its investment staff and non-executive directors. OC commenced operated in December 2000 with the launch of two long only small cap Australian equity funds, the OC...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.